Korro Bio
Korro Bio is seeking a highly motivated Associate Scientist to join the HTS-NGS operations team in a biotech environment focused on developing next-generation RNA editing technology and therapeutics. The role involves laboratory work, assay development, data analysis, and collaboration within a fast-paced company dedicated to creating transformative genetic medicines.
Korro Bio is a biotechnology company developing precision RNA‑editing therapeutics that edit a single letter on RNA to modulate biological pathways. Their mission is to translate this platform into genetic-medicine solutions for complex, prevalent diseases by advancing a focused therapeutic pipeline. The company emphasizes moving its science toward patient‑facing programs and resources (for example, work relevant to AATD) to deliver targeted, durable treatments.
Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook
4 days ago
Korro Bio (KRRO) Losses Of US$117.3 Million Test Bullish Narratives On Profitability
4 days ago
JPM26: Korro Bio Looks To Save Itself Despite Unenviable Position
Jan 16, 2026
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Korro Bio.
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Oruka Therapeutics (ORKA) and Gilead Sciences (GILD)
4 days ago